Fosamax (Alendronate) for Older Women: The Start-Low-Go-Slow Approach Explained

What Is Alendronate and Why Is It Used Almost Exclusively in Women?

Alendronate belongs to the bisphosphonate class of antiresorptive drugs. It works by binding to bone mineral and inhibiting osteoclasts, the cells that break bone down. Because estrogen normally restrains osteoclast activity, the estrogen withdrawal of menopause accelerates bone loss at a rate of 1-3% per year in trabecular bone for the first several post-menopausal years. That is the physiological reason alendronate's prescribing skews heavily female.

Bone loss is not an equal-opportunity process. Men lose bone gradually over decades; women lose a surge of trabecular bone tied directly to the menopausal estrogen decline. The Fracture Intervention Trial (FIT), the landmark RCT that established alendronate's efficacy, enrolled 2,027 postmenopausal women with low bone density. After 3 years, women randomized to alendronate 5-10 mg daily had a 47% relative risk reduction in hip fracture compared with placebo. That single number drives the bulk of osteoporosis prescribing in women today.

How Menopause Changes Bone Physiology

Estrogen suppresses RANKL, a signaling protein that activates osteoclasts. When ovarian estrogen production drops, RANKL activity rises, osteoclasts become more numerous and more active, and bone resorption outpaces formation. Women who enter menopause before age 45 (surgical or premature), and those who have had prolonged amenorrhea from eating disorders or hypothalamic dysfunction, carry a compounded lifetime deficit.

For a woman in her early 70s, the rapid bone loss phase has usually passed, but cumulative deficit is at its highest. That is precisely where geriatric dosing strategy matters most.

What "Start-Low-Go-Slow" Means in Practice

"Start-low-go-slow" is a geriatric prescribing principle applied broadly to medications with GI, renal, or CNS sensitivity concerns in older adults. For alendronate, the rationale is specific: esophageal tolerability and GI absorption are the main barriers to adherence in women over 70. The drug itself is not pharmacokinetically dose-escalated the way a cardiovascular drug would be; rather, the principle here means:

• Beginning at a lower dose (35 mg weekly, the osteopenia dose, rather than 70 mg) for 4-8 weeks if a woman reports prior GI sensitivity to NSAIDs or other oral drugs.
• Using the oral solution formulation (70 mg/100 mL) instead of tablets when swallowing is a concern.
• Advancing to full 70 mg weekly once tolerability is confirmed.

This WomanRx framework for geriatric alendronate titration, moving from 35 mg weekly to 70 mg weekly over a structured 4-8 week window based on GI tolerance, does not appear as a codified stepwise protocol in any current published guideline. It synthesizes the FDA-approved dosing flexibility in the Fosamax label, the American Geriatrics Society Beers Criteria context for GI-active drugs, and clinical experience managing adherence in older women. Use it as a conversation framework with your prescriber, not a substitute for individual clinical judgment.

Approved Doses and Formulations

The FDA-approved alendronate label specifies:

• Osteoporosis treatment in postmenopausal women: 70 mg once weekly or 10 mg once daily.
• Osteoporosis prevention in postmenopausal women: 35 mg once weekly or 5 mg once daily.
• Paget's disease: 40 mg once daily for 6 months (not relevant for most women reading this).

The 70 mg once-weekly tablet is by far the most commonly used formulation for treatment. The oral solution (70 mg in 100 mL) offers equivalent bioavailability and is helpful when tablet swallowing is difficult, but the solution must still be taken with plain water and the same upright-posture precautions apply.

Generic Availability and Cost

Generic alendronate 70 mg tablets are widely available and inexpensive, often under $10 per month at major pharmacy chains with discount programs. Brand Fosamax carries a substantial price premium with no pharmacokinetic advantage. If cost is a barrier, generic is appropriate.

Renal Dosing Restrictions

Alendronate is contraindicated when creatinine clearance falls below 35 mL/min. In older women, creatinine clearance often looks deceptively normal on a standard metabolic panel because older women have less muscle mass and produce less creatinine. A normal serum creatinine in a 75-year-old woman may correspond to an eGFR of 35-45 mL/min. Ask your prescriber to calculate your eGFR, not just glance at your creatinine number.

Why GI Tolerability Is the Central Geriatric Issue

Alendronate's oral bioavailability is only about 0.64% under ideal fasting conditions. Anything that disrupts that absorption window, food, coffee, other medications, or lying down after ingestion, drops efficacy further and concentrates unabsorbed drug against the esophageal mucosa.

Esophageal irritation is the most clinically significant GI adverse effect. The label requires:

1. Take with 6-8 oz (180-240 mL) of plain water only, not mineral water, coffee, juice, or tea.
2. Remain upright (sitting or standing) for at least 30 minutes afterward.
3. Do not eat, drink, or take other medications for at least 30 minutes.
4. Do not take at bedtime or before rising.

For a woman in her 70s or 80s who has gastroesophageal reflux disease (GERD), hiatal hernia, or difficulty remaining upright, these requirements can feel prohibitive. That is where the start-low-go-slow approach earns its place: beginning at 35 mg weekly gives the GI tract a lower-dose exposure during the learning period while the woman practices the correct administration routine.

When the GI Barrier Is Too High

If a woman cannot reliably remain upright for 30 minutes due to balance impairment, severe reflux, or esophageal stricture, oral alendronate may not be the right choice. Alternatives worth discussing with your prescriber include:

• Zoledronic acid (Reclast): 5 mg IV infusion once yearly. No GI exposure. Proven in the HORIZON Key Fracture Trial to reduce hip fracture by 41% vs. Placebo over 3 years in postmenopausal women.
• Denosumab (Prolia): 60 mg subcutaneous injection every 6 months. No renal restriction. Studied specifically in older women in the FREEDOM trial, which showed a 68% reduction in vertebral fracture over 3 years.
• Raloxifene (Evista): Oral SERM, 60 mg daily. Reduces vertebral fracture but not hip fracture. May worsen hot flashes, a meaningful consideration in women near menopause transition.

Sex-Specific Pharmacology: How Your Hormonal Status Changes the Picture

Postmenopausal Women (Most Common User)

This is the core indication. Estrogen deficiency is the mechanistic driver of the bone loss that alendronate counteracts. The American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology 2020 guidelines recommend initiating pharmacotherapy in postmenopausal women with:

• A hip or spine T-score of <-2.5 on DXA.
• A T-score between -1.0 and -2.5 with a FRAX 10-year major osteoporotic fracture probability of ≥20%, or hip fracture probability of ≥3%.
• A prior low-trauma vertebral or hip fracture, regardless of DXA score.

Perimenopausal Women

Women in perimenopause (typically 45-55, though the range is wide) are generally not the primary target for alendronate. Bone loss accelerates during the menopausal transition but has not yet reached the cumulative deficit that usually triggers treatment. Hormone therapy, if appropriate, addresses bone loss as a secondary benefit during this stage. If a perimenopausal woman has a prior fragility fracture or very low T-score, the conversation changes.

Women with PCOS

Polycystic ovary syndrome (PCOS) presents a mixed bone-health picture. Androgen excess and chronic anovulation with estrogen deficiency periods can affect bone density in unpredictable directions. Some data suggest bone mineral density is relatively preserved in PCOS due to higher androgen levels, but women with PCOS who achieve significant weight loss through GLP-1 receptor agonists or bariatric surgery may accelerate bone loss and reach treatment thresholds earlier.

Women with Eating Disorders or Hypothalamic Amenorrhea

Prolonged estrogen deficiency from hypothalamic amenorrhea causes bone loss that resembles accelerated menopause. These women may qualify for alendronate at much younger ages. The ACOG Committee Opinion on bone health in eating disorders emphasizes that treating the underlying condition and restoring estrogen is the primary intervention; bisphosphonates are typically added when recovery stalls or bone loss is severe.

Women with Glucocorticoid-Induced Osteoporosis

Women on long-term glucocorticoids (prednisone ≥5 mg/day for ≥3 months) face a separate pathway. The ACR 2022 guidelines on glucocorticoid-induced osteoporosis recommend oral bisphosphonates as first-line pharmacotherapy in this setting. Alendronate 70 mg weekly is one of the named agents. Women on glucocorticoids for autoimmune conditions (lupus, rheumatoid arthritis) are a particularly common population needing this intervention.

Pregnancy, Lactation, and Contraception: The Non-Negotiable Section

Alendronate is contraindicated in pregnancy. This is not a theoretical concern; it is a physiological one. Bisphosphonates incorporate into bone and are released slowly over years to decades. Animal studies show fetal harm (hypocalcemia, skeletal abnormalities) at doses below the human therapeutic range.

Pregnancy Category and Human Data

Alendronate carries FDA Pregnancy Category C under the old classification system (now replaced by narrative labeling). The updated label states: "There are no adequate and well-controlled studies in pregnant women. Alendronate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus." In practical terms, that means: do not use alendronate in pregnancy. The long skeletal half-life means bisphosphonate exposure may persist for years after stopping the drug, so any woman of reproductive age who is prescribed alendronate needs a frank conversation about conception timing.

The case series on bisphosphonate use in pregnancy is small and reassuring for accidental first-trimester exposures, with no consistent pattern of major malformations identified in humans to date. But "no consistent pattern yet identified" is not safety data. Intentional use in pregnancy is not justified.

Contraception Requirement

Any woman of reproductive age started on alendronate should use reliable contraception. This is particularly relevant for:

• Women with premenopausal osteoporosis (due to eating disorders, glucocorticoid therapy, or premature menopause).
• Women with PCOS who may have irregular cycles but are not reliably anovulatory.
• Women who are peri-menopausal but have not confirmed menopause (12 consecutive months without a period).

If you are considering pregnancy within the next 2-3 years and you need osteoporosis treatment, discuss alternatives with your clinician. Denosumab carries different considerations (its effect reverses rapidly off-drug, which carries its own risk of rebound bone loss), and anabolic agents like teriparatide are not used in pregnancy either. This is a nuanced conversation that warrants a specialist referral.

Lactation

Alendronate transfer into breast milk has not been adequately studied in humans. The FDA label states it is not known whether alendronate is excreted in human milk. Given the potential for serious adverse effects in a nursing infant and the very low oral bioavailability of alendronate even under ideal conditions (which would affect infant absorption), the decision about whether to use alendronate while breastfeeding requires individualized risk-benefit discussion. Postpartum bone loss is a recognized phenomenon, but for most women it reverses with weaning; pharmacotherapy during lactation is rarely indicated.

Monitoring Before and During Treatment

Before Starting

Your prescriber should check:

| Test | Reason | |------|---------| | Serum calcium | Hypocalcemia is a contraindication; alendronate will worsen it | | 25-hydroxyvitamin D | Correct deficiency before starting; inadequate vitamin D blunts response | | eGFR (not just creatinine) | Contraindicated if <35 mL/min | | DXA scan (spine and hip) | Establishes baseline T-score | | FRAX score | Guides treatment threshold |

Calcium and vitamin D adequacy are not optional add-ons. The National Osteoporosis Foundation (now the Bone Health and Osteoporosis Foundation) recommends 1,200 mg/day total calcium (diet plus supplement) and 800-1,000 IU/day vitamin D for women over 50. Alendronate works poorly in vitamin D-deficient women because calcium absorption is impaired.

During Treatment

• Repeat DXA at 1-2 years after starting to confirm response.
• A bone turnover marker such as serum CTX (C-terminal telopeptide) can be drawn at 3-6 months to confirm biochemical response before waiting for DXA.
• Annual review of GI tolerability, renal function, and continued indication.

Drug Holiday: The 3-5 Year Decision

After 3-5 years of alendronate, the evidence supports a reassessment. The FLEX trial randomized women who had taken alendronate for 5 years to continue or discontinue for another 5 years. Women who discontinued maintained much of their bone density through the skeletal reservoir of retained bisphosphonate, and the risk of non-vertebral fractures was similar between groups. Women at highest risk (femoral neck T-score <-2.5 or prior vertebral fracture) gained more from continuation.

The drug holiday concept does not mean stopping and forgetting. It means a structured break with continued monitoring and a plan to restart if bone density falls.

Who This Drug Is Right For, and Who Should Think Twice

Strong Candidates

• Postmenopausal women aged 65+ with T-score <-2.5 at hip or spine.
• Women of any age with a prior low-trauma hip or vertebral fracture.
• Women on long-term glucocorticoids (≥5 mg prednisone daily for ≥3 months) at any age.
• Women with premature ovarian insufficiency who have low bone density and for whom hormone therapy alone has not stabilized bone loss.

Women Who Need a Different Conversation First

• Women with eGFR <35 mL/min. Oral bisphosphonates are contraindicated here; denosumab or raloxifene are options.
• Women with active upper GI disease (esophagitis, active peptic ulcer, severe GERD). IV zoledronic acid is a cleaner choice.
• Women who cannot remain upright for 30 minutes after dosing due to balance disorders or neurological conditions.
• Women planning pregnancy within 2-3 years.
• Women with hypocalcemia or uncorrected severe vitamin D deficiency (correct these first, then reassess).

The Atypical Femur Fracture Conversation

Long-term bisphosphonate use (typically beyond 5 years) carries a small absolute risk of atypical femoral fractures, stress fractures that occur with minimal or no trauma in the subtrochanteric or femoral shaft region. The FDA safety communication on atypical femoral fractures estimates the risk at approximately 3.2-50 cases per 100,000 person-years, increasing with duration of use. This is rare in absolute terms but warrants discussion at the 3-5 year mark and is part of why the drug holiday framework exists.

Thigh or groin pain that is new and persistent in a woman on long-term alendronate should prompt imaging (X-ray of the full femur) to rule out an early atypical fracture before it completes.

Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) is rare with oral alendronate at osteoporosis doses. The risk is substantially higher with IV bisphosphonates used in oncology at much higher doses. For a woman taking 70 mg weekly for osteoporosis, the estimated incidence of ONJ is roughly 1 in 10,000 to 1 in 100,000 patient-years. Dental hygiene and informing your dentist of bisphosphonate use before any invasive dental procedure remain reasonable precautions. This risk should not prevent most women from taking an indicated medication.

The Evidence Gap: What We Know (and Don't) About Alendronate Specifically in Older Women

The FIT trial was restricted to women aged 55-80 with low bone density or prior vertebral fracture. Women over 80 were not enrolled. Most titration studies for bisphosphonates are pharmacokinetic studies in relatively healthy volunteers, not frail older women with polypharmacy, renal aging, and GI comorbidities. This is a real gap. The geriatric prescribing literature acknowledges that bisphosphonate tolerability data in women over 80 is extrapolated from younger trial populations, not directly measured. The start-low-go-slow approach described in this article is a clinically reasoned response to that gap, not a protocol validated in a large RCT of octogenarians.

The Women's Health Initiative (WHI) observational data support bisphosphonate fracture reduction in older real-world women, but observational data carries confounding. The short answer: the fracture reduction benefit is well established; the optimal titration strategy in the oldest old is based on clinical consensus and physiology, not a dedicated trial.

A direct quote from the 2022 American Geriatrics Society (AGS) Beers Criteria is instructive: oral bisphosphonates are not listed as potentially inappropriate in older adults, but the criteria note that "precautions regarding administration instructions are especially important in older adults with physical or cognitive limitations." That phrase captures why individualized titration matters.

Practical Administration Guide for Older Women

The correct technique for taking alendronate is specific enough to warrant its own section. Getting this wrong is the most common reason alendronate fails to be tolerated.

Step-by-Step Weekly Dose Routine

1. Choose one day per week and keep it consistent. Sunday morning is popular because it is easy to remember and easier to arrange 30 minutes upright before the day begins.
2. Wake, do not eat, do not drink coffee or juice. Take your alendronate tablet (or measure the oral solution) with a full 8 oz glass of plain tap or still water only.
3. Sit upright in a chair or stand. Do not go back to bed.
4. Wait 30 minutes. Then eat breakfast, take other medications, and have your coffee.
5. If you miss your weekly dose, take it the next morning. Do not take two doses on the same day.

Calcium and Vitamin D Timing

Do not take calcium supplements within 2 hours of alendronate. Calcium binds alendronate in the GI tract and blocks absorption. Take your calcium supplement with lunch or dinner, not at the same time as the alendronate dose.

FAQs